OXFORD, England—October 31, 2022 04:00 AM Eastern Daylight Time—Ochre Bio, an innovator in chronic liver disease drug development, today announced its participation in upcoming investor and industry conferences.
Ochre Bio, an RNA therapeutics company focused on chronic liver and cardiometabolic diseases, announced today the formation of its scientific strategy board (SSB) to support the maturation of its platforms and pipeline of liver disease therapeutics.
Ochre Bio Raises $30M Series A Financing for the Development of RNA Therapies for Chronic Liver Diseases
Proceeds to support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases.
OXFORD, England–Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced today to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a […]
OXFORD, England–Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, today announced the closing of a $9.6M seed financing round led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek. The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand […]